Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender

C Belani; J von Pawel; A Pluzanska; V Gorbounova; E Kaukel; K Mattson; R Ramlau; P Fidias; M Millward; F Fossella

doi:10.1016/S0169-5002(05)80945-6

Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender

C Belani, J von Pawel, A Pluzanska, V Gorbounova, E Kaukel, K Mattson, R Ramlau, P Fidias, M Millward, F Fossella

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

8 Citations (Web of Science)

Original language	English
Article number	P452
Pages (from-to)	S235-S236
Number of pages	2
Journal	Lung Cancer
Volume	49
DOIs	https://doi.org/10.1016/S0169-5002(05)80945-6
Publication status	Published - Jul 2005
Externally published	Yes
Event	11th World Conference on Lung Cancer - Barcelona, Spain Duration: 3 Jul 2005 → 6 Jul 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0169-5002(05)80945-6

Cite this

Belani, C., von Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E., Mattson, K., Ramlau, R., Fidias, P., Millward, M., & Fossella, F. (2005). Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender. Lung Cancer, 49, S235-S236. Article P452. https://doi.org/10.1016/S0169-5002(05)80945-6

@article{0ad4d3803f9148cf85d3298c539d68c7,

title = "Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender",

author = "C Belani and \{von Pawel\}, J and A Pluzanska and V Gorbounova and E Kaukel and K Mattson and R Ramlau and P Fidias and M Millward and F Fossella",

year = "2005",

month = jul,

doi = "10.1016/S0169-5002(05)80945-6",

language = "English",

volume = "49",

pages = "S235--S236",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier",

note = "11th World Conference on Lung Cancer ; Conference date: 03-07-2005 Through 06-07-2005",

}

Belani, C, von Pawel, J, Pluzanska, A, Gorbounova, V, Kaukel, E, Mattson, K, Ramlau, R, Fidias, P, Millward, M & Fossella, F 2005, 'Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender', Lung Cancer, vol. 49, P452, pp. S235-S236. https://doi.org/10.1016/S0169-5002(05)80945-6

Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender. / Belani, C; von Pawel, J; Pluzanska, A et al.
In: Lung Cancer, Vol. 49, P452, 07.2005, p. S235-S236.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC)

T2 - 11th World Conference on Lung Cancer

AU - Belani, C

AU - von Pawel, J

AU - Pluzanska, A

AU - Gorbounova, V

AU - Kaukel, E

AU - Mattson, K

AU - Ramlau, R

AU - Fidias, P

AU - Millward, M

AU - Fossella, F

PY - 2005/7

Y1 - 2005/7

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=uwapure5-25&SrcAuth=WosAPI&KeyUT=WOS:000231307801373&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1016/S0169-5002(05)80945-6

DO - 10.1016/S0169-5002(05)80945-6

M3 - Abstract/Meeting Abstract

SN - 0169-5002

VL - 49

SP - S235-S236

JO - Lung Cancer

JF - Lung Cancer

M1 - P452

Y2 - 3 July 2005 through 6 July 2005

ER -

Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender

UN SDGs

Access to Document

Other files and links

Cite this